| |
|
|
|
|
|
 |
| |
|
ÇÏÀÌÆÊÁÖ HIPHARM INJ.[fenoldopam mesylate]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A05607451]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/2ml/¾ÚÇÃ(2007.11.15)(ÇöÀç¾à°¡)
\85,000 ¿ø/2ml/¾ÚÇÃ(2005.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Æ÷À塤À¯Åë´ÜÀ§ |
2ML/¾ÚÇÃ |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¸»´Ü Àå±âÀÇ ±â´É¾ÇÈ·Î ÀÎÇÑ ¾Ç¼º°íÇ÷¾ÐÀ» Æ÷ÇÔÇÏ¿©, ½Å¼ÓÇÑ °¡¿ªÀû Ç÷¾ÐÁ¶ÀýÀ» ÇÊ¿ä·Î ÇÏ´Â ÁßÁõ °íÇ÷¾Ð ȯÀÚÀÇ ÀÔ¿ø½Ã ´Ü±â°£(ÃÖ´ë 48½Ã°£) Ä¡·á
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:460601BIJ ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
|
| ±Ý±â |
ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ ´ëÇØ °ú¹ÎÁõ ¶Ç´Â °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
ÇǷξÆÈ²»ê³ªÆ®·ý, ¾ÆÈ²»êÀÌ ÇÔÀ¯µÇ¾î ÀÖ¾î ¾Æ³ªÇʶô½Ã ÁõÈıº°ú °°Àº ¾Ë·¯Áö ¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç, ÀϺΠ°¨¼ö¼º ȯÀÚ¿¡¼ »ý¸íÀ» À§ÇùÇÒ Á¤µµ ¶Ç´Â À̺¸´Ù ¾àÇÑ Ãµ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ÀÏ¹Ý »ç¶÷¿¡¼ÀÇ ¾ÆÈ²»ê°¨¼ö¼º¿¡ ´ëÇÑ ÃѰýÀûÀÎ ºóµµ´Â ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª ³·Àº °ÍÀ¸·Î º¸À̸ç, ¾ÆÈ²»ê¿¡ ´ëÇÑ °¨¼ö¼ºÀº ºñõ½ÄȯÀÚº¸´Ù õ½ÄȯÀÚ¿¡¼ ºó¹øÇÑ °ÍÀ¸·Î ³ªÅ¸³µ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
ÀÌ ¾àÀº ¿ë·®ÀÇÁ¸ÀûÀÎ Ç÷¾Ð°Çϸ¦ ÀÏÀ¸Å°°í ½ÉÀå¹Úµ¿À» Áõ°¡½ÃŲ´Ù. ¸»´ÜÀå±â »óÇØ ȯÀÚÀÇ ÁßÁõ°íÇ÷¾Ð¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè¿¡¼ 3%ÀÇ È¯ÀÚ°¡ Ç÷¾ÐÀÇ °úµµÇÑ °ÇÏ·Î ÀÎÇØ Å»¶ôµÇ¾ú´Ù. ½ÉÀå¹Úµ¿Áõ°¡´Â ½ÇÁúÀûÀ¸·Î °üÂûµÈ ¹Ù´Â ¾øÁö¸¸ ÀÌ·ÐÀûÀ¸·Î ÇãÇ÷¼º ½ÉÀ帶ºñ ¶Ç´Â ½ÉºÎÀüÀÇ ¾Çȸ¦ ¾ß±âÇÒ ¼ö ÀÖ´Ù. ÀÌ ¾àÀÇ »ç¿ë°ú °ü·ÃµÈ ÀϹÝÀûÀÎ ÀÌ»ó¹ÝÀÀÀº µÎÅë, ÇǺÎÈ®Àå (È«Á¶), ±¸¿ª, ÀúÇ÷¾ÐÀÌ °¢°¢ ȯÀÚÀÇ 5% À̻󿡼 º¸°íµÇ¾ú´Ù.
|
| »óÈ£ÀÛ¿ë |
1) µð±âÅ»¸®½º, ´ÏÆ®·Î±Û¸®¼¼¸° ¼³ÇÏÁ¦¿ÍÀÇ »óÈ£ÀÛ¿ëÀº ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù.
2) ³ë¸£¾Æµå·¹³¯¸°ÀÇ Ç÷Á߳󵵸¦ Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î MAO¾ïÁ¦Á¦¿Í º´¿ëÅõ¿©½Ã ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
3) º£Å¸Â÷´ÜÁ¦, ¾ËÆÄÂ÷´ÜÁ¦, Ä®½·Ã¤³Î Â÷´ÜÁ¦, ¾ÈÁö¿ÀÅٽŠÀüȯȿ°ú ¾ïÁ¦Á¦, ÀÌ´¢Á¦µîÀÇ Ç×°íÇ÷¾Ð¾à¹°°ú º´¿ë½Ã ¿¹ÃøÇÒ ¼ö ¾ø´Â ÀúÇ÷¾ÐÀÌ ¾ß±âµÉ ¼ö ÀÖÀ¸¹Ç·Î, °¡´ÉÇÑ ÇÑ º´¿ëÅõ¿©¸¦ ÇÇÇÑ´Ù. |
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
fenoldopam¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to ¥á2-adrenoceptors. It has no significant affinity for D2-like receptors, ¥á1 and ¥â-adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or ¥á or ¥â -adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.
|
| Pharmacology |
fenoldopam¿¡ ´ëÇÑ Pharmacology Á¤º¸ Fenoldopam antagonizes D1-like dopamine receptors, binds to ¥á2-adrenoceptors, increasing renal blood flow.
|
| Absorption |
fenoldopam¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Toxicity |
fenoldopam¿¡ ´ëÇÑ Toxicity Á¤º¸ The most likely reaction of overdose would be excessive hypotension which should be treated with drug discontinuation and appropriate supportive measures.
|
| Drug Interactions |
fenoldopam¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
fenoldopam¿¡ ´ëÇÑ Description Á¤º¸ A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. [PubChem]
|
| Dosage Form |
fenoldopam¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Injection, solution Intravenous drip
|
| Drug Category |
fenoldopam¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypertensive AgentsDopamine AgonistsVasodilator Agents
|
| Smiles String Canonical |
fenoldopam¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
|
| Smiles String Isomeric |
fenoldopam¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ OC1=CC=C(C=C1)[C@@H]1CNCCC2=C(Cl)C(O)=C(O)C=C12
|
| InChI Identifier |
fenoldopam¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
|
| Chemical IUPAC Name |
fenoldopam¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2012-03-02
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|